Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Price Target at $131.86

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the firm, MarketBeat reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $131.86.

Several equities research analysts have recently weighed in on the stock. Truist Financial reaffirmed a “buy” rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. JMP Securities reaffirmed a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st.

Insider Buying and Selling

In related news, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Janus Henderson Group PLC raised its stake in shares of Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after acquiring an additional 257,022 shares in the last quarter. Geode Capital Management LLC increased its stake in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares in the last quarter. T. Rowe Price Investment Management Inc. increased its stake in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after purchasing an additional 435,445 shares in the last quarter. Reinhart Partners LLC. increased its stake in Lantheus by 9.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock valued at $122,280,000 after purchasing an additional 123,282 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Lantheus by 2.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider’s stock valued at $120,510,000 after purchasing an additional 30,891 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH opened at $79.94 on Friday. The company has a 50 day moving average price of $91.43 and a 200-day moving average price of $97.79. Lantheus has a fifty-two week low of $56.06 and a fifty-two week high of $126.89. The stock has a market capitalization of $5.56 billion, a PE ratio of 13.30 and a beta of 0.44.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.